Children | Free Full-Text | High-Risk Neuroblastoma Treatment Review
Randomized Trial of Prophylactic Granulocyte Colony-Stimulating Factor During Rapid COJEC Induction in Pediatric Patients With High-Risk Neuroblastoma: The European HR-NBL1/SIOPEN Study | Journal of Clinical Oncology
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial - The Lancet Oncology
Clinically relevant treatment of PDX models reveals patterns of neuroblastoma chemoresistance | Science Advances
![PDF] Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/61dfb3a5ee37540ef03aaa30a65508f621b16f2b/4-Table1-1.png "PDF] Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study | Semantic Scholar")
PDF] Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study | Semantic Scholar
Clinically-relevant treatment of PDX models reveals patterns of neuroblastoma chemoresistance | bioRxiv
Randomized Trial of Prophylactic Granulocyte Colony-Stimulating Factor During Rapid COJEC Induction in Pediatric Patients With High-Risk Neuroblastoma: The European HR-NBL1/SIOPEN Study | Journal of Clinical Oncology
Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR - Annals of Oncology
IJMS | Free Full-Text | MTHFR and VDR Polymorphisms Improve the Prognostic Value of MYCN Status on Overall Survival in Neuroblastoma Patients
Forest plot of comparison: 1 Rapid COJEC versus standard induction,... | Download Scientific Diagram
HIGH-RISK NEUROBLASTOMA: STANDARD CLINICAL PRACTICE RECOMMENDATIONS Moderation: Ruth Ladenstein
HIGH-RISK NEUROBLASTOMA: STANDARD CLINICAL PRACTICE RECOMMENDATIONS Moderation: Ruth Ladenstein
Management of neuroblastoma in limited-resource settings
A study looking at treatment for high risk neuroblastoma (HR/NBL2/SIOPEN) | Cancer Research UK
Topotecan-vincristine-doxorubicin in stage 4 high risk neuroblastoma patients failing to achieve a complete metastatic response to rapid COJEC : a SIOPEN study
JOURNAL CLUB HIGH-DOSE RAPID AND STANDARD INDUCTION CHEMOTHERAPY FOR PATIENTS AGED OVER 1 YEAR WITH STAGE 4 NEUROBLASTOMA: A RANDOMISED TRIAL † Lancet. - ppt download
Thieme E-Books & E-Journals -
Clinically relevant treatment of PDX models reveals patterns of neuroblastoma chemoresistance | Science Advances
Long-term follow-up of high-risk neuroblastoma survivors treated with high-dose chemotherapy and stem cell transplantation rescue | Bone Marrow Transplantation
High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial - The Lancet Oncology
Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SI
Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1. - Abstract - Europe PMC
G-CSF counteracts chemotherapy toxicity in neuroblastoma - Document - Gale Academic OneFile
HIGH-RISK NEUROBLASTOMA: STANDARD CLINICAL PRACTICE RECOMMENDATIONS Moderation: Ruth Ladenstein
Clinical impact of primary tumour 123ImIBG response to induction chemotherapy in children with high-risk neuroblastoma | International Journal of Clinical Oncology
Treatment and management of newly diagnosed patients with high-risk neuroblastoma (not patients currently registered on HR-NBL-1
Browse Preprints - Authorea
